BLUE News Alert Bluebird Bio Inc (BLUE) 91.26 01/03/2015 13:

New Post Public Reply Private Reply Replies (0) Message Board

Jan 3, 2015 at 2:29 PM

Bluebird Bio Inc (BLUE) 91.26 $BLUE

How These 3 Stocks Doubled Investors' Money in Q4
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 03, 9:31AM CST
Source: Flickr user Tax Credits Most of the time, life-changing financial gains are generated over the long haul, not in the blink of an eye. However, sometimes stocks can put up jaw-dropping returns over a short period of time too. For example,...
BLUE: 91.26 (-0.46), ISIS: 61.57 (-0.17), ALNY: 97.77 (+0.77), OVAS: 45.83 (+1.61), GILD: 94.91 (+0.65), RGLS: 17.19 (+1.15), CELG: 113.52 (+1.66)

The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 91.26 (-0.46), TTPH: 39.72 (+0.01), AVNR: 16.94 (-0.01), SWKS: 73.32 (+0.61), CMRX: 41.78 (+1.52), ACHN: 13.33 (+1.08), HA: 25.27 (-0.78), RCPT: 124.81 (+2.30), PTCT: 51.00 (-0.77), AGIO: 109.76 (-2.28)

Cellectis Is Late To The CAR-T Cell Race, But Could Finish First
Intrepid Investor - at Seeking Alpha - Fri Jan 02, 3:21PM CST

BLUE: 91.26 (-0.46), BLCM: 22.86 (-0.18), KITE: 60.61 (+2.94), JUNO: 48.25 (-3.97), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41), CELG: 113.52 (+1.66)

Biotech Stocks 2014: The Best, Worst and Fastest-Growing
at The Street - Fri Jan 02, 7:33AM CST
Once again, biotech stocks greatly outperformed the broader market in 2014.
BLUE: 91.26 (-0.46), OVAS: 45.83 (+1.61), ACHN: 13.33 (+1.08), RCPT: 124.81 (+2.30), AGIO: 109.76 (-2.28)

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens
at The Street - Mon Dec 29, 5:00AM CST
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
BLUE: 91.26 (-0.46), NWBO: 5.42 (+0.07), GILD: 94.91 (+0.65), DNDN: 0.13 (-0.02), ICPT: 159.49 (+3.49), JUNO: 48.25 (-3.97), GALE: 1.56 (+0.05), AGIO: 109.76 (-2.28), AEGR: 21.58 (+0.64), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), MNKD: 5.64 (+0.42), CELG: 113.52 (+1.66)

INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into bluebird bio, Inc. Regarding Possible Breaches of Fiduciary Duty
Business Wire - Tue Dec 23, 12:41PM CST
Levi & Korsinsky, LLP is investigating bluebird bio, Inc. (Nasdaq: BLUE) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
BLUE: 91.26 (-0.46)

3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 91.26 (-0.46), GSK: 42.37 (-0.37), BMY: 59.51 (+0.48), NVS: 92.25 (-0.41), CELG: 113.52 (+1.66), FPRX: 27.71 (+0.71), EXEL: 1.65 (+0.21)

Cramer's Mad Money - Look At Red Hat Go (12/19/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Dec 21, 4:26AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 19. CEO Interview, James Whitehurst, Red Hat (NYSE: RHT ) "Look at Red Hat ( RHT ) run." The stock dominates Open Source software for...
BLUE: 91.26 (-0.46), GPRO: 66.87 (+3.65), AVP: 9.31 (-0.08), SYNA: 64.25 (-4.59), NKE: 95.03 (-1.12), SKX: 55.74 (+0.49), DECK: 89.74 (-1.30), DIS: 93.75 (-0.44), CSIQ: 24.69 (+0.50), PAYX: 46.24 (+0.07), RDNT: 8.66 (+0.12), KITE: 60.61 (+2.94), RHT: 68.99 (-0.15), HAWK: 37.01 (-1.79), JUNO: 48.25 (-3.97), PAY: 37.35 (+0.15), WAG: 76.05 (-0.49)

The Winners for Best and Worst Biotech CEOs of 2014 Are...
at The Street - Thu Dec 18, 9:01AM CST
Congrats to David Schenkhein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
BLUE: 91.26 (-0.46), RTRX: 12.67 (+0.43), AGIO: 109.76 (-2.28)

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses
at The Street - Thu Dec 18, 8:35AM CST
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
BLUE: 91.26 (-0.46), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), SGMO: 15.27 (+0.06)

Juno Therapeutics: Saving The Best Biotech IPO For Last In 2014
Chris Katje - at Seeking Alpha - Wed Dec 17, 10:13AM CST

BLUE: 91.26 (-0.46), KITE: 60.61 (+2.94), JUNO: 48.25 (-3.97)

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 91.26 (-0.46), BIIB: 342.01 (+2.56), VRTX: 123.07 (+4.27), NBIX: 22.84 (+0.50), GILD: 94.91 (+0.65), ARWR: 7.71 (+0.33), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), CTIC: 2.40 (+0.04), CEMP: 22.89 (-0.62), BMY: 59.51 (+0.48)

'Mad Money' Lightning Round: Enbridge Energy Partners Is a Great Stock
at The Street - Wed Dec 17, 5:00AM CST
Cramer says to wait on buying Chevron and Bluebird Bio until their shares are lower and stay away from EV Energy Partners.
BLUE: 91.26 (-0.46), TTWO: 28.09 (+0.06), ATVI: 20.13 (-0.02), SAIC: 49.50 (-0.03), EVEP: 21.01 (+1.74), ONVO: 7.29 (+0.04), TRN: 28.28 (+0.27), CVX: 112.58 (+0.40), EEP: 40.55 (+0.65)

Cramer's Lightning Round - Chevron Is Worth The Wait (12/16/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Dec 17, 4:03AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday December 16. Bullish Calls: Chevron (NYSE: CVX ): "CVX has a nice yield and it is good. You are going to have to wait till around $95 with a...
BLUE: 91.26 (-0.46), ATVI: 20.13 (-0.02), SAIC: 49.50 (-0.03), EVEP: 21.01 (+1.74), ONVO: 7.29 (+0.04), TRN: 28.28 (+0.27), CVX: 112.58 (+0.40), EEP: 40.55 (+0.65)

Jim Cramer's 'Mad Money' Recap: Goldilocks vs. 3 Bears, Where Nothing Is Just Right
at The Street - Tue Dec 16, 7:10PM CST
The bears may have won the day but there's still hope, Cramer says.
BLUE: 91.26 (-0.46), 77.49 (+0.59), RH: 95.14 (-0.87), COLM: 44.33 (-0.21), EEP: 40.55 (+0.65), TTWO: 28.09 (+0.06), ATVI: 20.13 (-0.02), PBR: 6.76 (-0.54), SAIC: 49.50 (-0.03), EVEP: 21.01 (+1.74), ONVO: 7.29 (+0.04), TRN: 28.28 (+0.27), CVX: 112.58 (+0.40)

Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 91.26 (-0.46), BMRN: 92.17 (+1.77), TGTX: 16.33 (+0.49), BMY: 59.51 (+0.48), MACK: 11.43 (+0.13), FMI: 22.18 (-0.04), RNA: 18.83 (+0.08), GWPH: 70.04 (+2.36), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), NLNK: 43.65 (+3.90), ICPT: 159.49 (+3.49), THLD: 3.43 (+0.25), CEMP: 22.89 (-0.62), NVS: 92.25 (-0.41)

bluebird (BLUE) is in Overbought Territory: What's Next?

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...